Research Article

Gastrointestinal Dysfunctions Are Associated with IL-10 Variants in Parkinson’s Disease

Table 1

Demographic data and clinical characteristics of PD patients in both IL-10 rs1800871 and rs1800872 carriers and noncarriers (numerical variables).

CarriersNoncarrierspSC
NX ± SNX ± S

Age17762.64 ± 10.4619063.23 ± 9.49NANA
UPDRS I1652.30 ± 1.971742.32 ± 2.370.977−0.002
UPDRS II16512.88 ± 6.4917413.78 ± 8.080.319−0.054
UPDRS III17226.76 ± 14.7017829.26 ± 16.010.157−0.075
H-Y1562.27 ± 0.931612.40 ± 0.960.211−0.070
LEDD166556.08 ± 281.23178517.52 ± 314.510.2010.070
PDSS67106.39 ± 23.3370107.13 ± 27.260.657−0.039
NMSS-D1640.97 ± 2.03680.79 ± 1.780.4920.062
NMSS-D26410.88 ± 6.67689.79 ± 6.950.3340.087
NMSS-D3647.97 ± 9.78687.71 ± 9.520.862−0.016
NMSS-D4641.61 ± 2.58681.69 ± 3.230.8180.020
NMSS-D5643.25 ± 3.82684.44 ± 4.680.235−0.105
NMSS-D6644.25 ± 4.58686.07 ± 4.760.0230.198
NMSS-D7646.55 ± 5.29687.18 ± 6.020.649−0.040
NMSS-D8640.92 ± 3.05680.53 ± 2.430.5240.057
PDQ-396436.33 ± 25.687032.91 ± 23.390.3760.079
CCI1770.12 ± 0.401900.17 ± 0.500.259−0.059

Abbreviations: UPDRS I, II, III, Unified Parkinson’s Disease Rating Scale part I, II, III; H-Y, Hoehn and Yahr Scale; LEDD, Levodopa equivalent daily dose; PDSS, Parkinson’s Disease Sleep Scale; NMSS, Nonmotor Symptoms Scale; NMSS-D1, NMSS-cardiovascular; NMSS-D2, NMSS-sleep/fatigue; NMSS-D3, NMSS-mood/apathy; NMSS-D4, NMSS-perception/hallucinations; NMSS-D5, NMSS-attention/memory; NMSS-D6, NMSS-gastrointestinal; NMSS-D7, NMSS-urinary; NMSS-D8, NMSS-sexual dysfunction; PDQ-39, the 39-item Parkinson’s Disease Questionnaire; CCI, Charlson Comorbidity Index. N represented the total number of carriers and noncarriers of both IL-10 rs1800871 and rs1800872 in PD patients. Numerical variable was presented as mean and standard deviation (X ± S). values <0.05 were considered of statistical significance and was shown in boldface text. SC, standardized coefficient; NA, not available.